KU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul 02841, Korea.
Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology, Seoul 02456, Korea.
Int J Mol Sci. 2022 May 30;23(11):6123. doi: 10.3390/ijms23116123.
The SARS-CoV-2 pandemic has created a global public crisis and heavily affected personal lives, healthcare systems, and global economies. Virus variants are continuously emerging, and, thus, the pandemic has been ongoing for over two years. Vaccines were rapidly developed based on the original SARS-CoV-2 (Wuhan-Hu-1) to build immunity against the coronavirus disease. However, they had a very low effect on the virus' variants due to their low cross-reactivity. In this study, a multivalent SARS-CoV-2 vaccine was developed using ferritin nanocages, which display the spike protein from the Wuhan-Hu-1, B.1.351, or B.1.429 SARS-CoV-2 on their surfaces. We show that the mixture of three SARS-CoV-2 spike-protein-displaying nanocages elicits CD4 and CD8 T cells and B-cell immunity successfully in vivo. Furthermore, they generate a more consistent antibody response against the B.1.351 and B.1.429 variants than a monovalent vaccine. This leads us to believe that the proposed ferritin-nanocage-based multivalent vaccine platform will provide strong protection against emerging SARS-CoV-2 variants of concern (VOCs).
SARS-CoV-2 大流行造成了全球公共危机，严重影响了个人生活、医疗保健系统和全球经济。病毒变体不断出现，因此大流行已经持续了两年多。最初的 SARS-CoV-2（武汉-Hu-1）疫苗被迅速开发出来，以建立针对冠状病毒疾病的免疫力。然而，由于它们的交叉反应性低，它们对病毒变体的效果非常低。在这项研究中，使用铁蛋白纳米笼开发了一种多价 SARS-CoV-2 疫苗，其表面展示了来自武汉-Hu-1、B.1.351 或 B.1.429 SARS-CoV-2 的刺突蛋白。我们表明，三种 SARS-CoV-2 刺突蛋白展示纳米笼的混合物可成功在体内引发 CD4 和 CD8 T 细胞和 B 细胞免疫。此外，它们产生的针对 B.1.351 和 B.1.429 变体的抗体反应比单价疫苗更一致。这使我们相信，所提出的基于铁蛋白纳米笼的多价疫苗平台将为应对新出现的 SARS-CoV-2 变体提供强大的保护。
